OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis

Abaloparatide (ABL) is a novel, selective activator of the PTH1 receptor signaling pathway. In the 18-month Phase 3 ACTIVE study in women with postmenopausal osteoporosis (OP) (NCT01343004), ABL significantly increased bone mineral density (BMD), and decreased the risk of new vertebral (VF), nonvert...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Main Authors: Lane, Nancy, Mitlak, Bruce, Weiss, Richard, Wang, Yamei, Valenzuela, Guillermo, Bilezikian, John
Formato: Artigo
Idioma:Inglês
Publicado: Endocrine Society 2019
Assuntos:
Bone and Mineral Metabolism
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6554836/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR03-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares